Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/139342METHOD FOR MANUFACTURING SOLAR CELL, AND SOLAR CELL MANUFACTURED THEREBY
WO 30.06.2022
Int.Class H01L 51/42
HELECTRICITY
01BASIC ELECTRIC ELEMENTS
LSEMICONDUCTOR DEVICES; ELECTRIC SOLID STATE DEVICES NOT OTHERWISE PROVIDED FOR
51Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof
42specially adapted for sensing infra-red radiation, light, electromagnetic radiation of shorter wavelength, or corpuscular radiation; specially adapted either for the conversion of the energy of such radiation into electrical energy or for the control of electrical energy by such radiation
Appl.No PCT/KR2021/019262 Applicant HANWHA SOLUTIONS CORPORATION Inventor JUNG, Kwang Ho
The present invention relates to a method for manufacturing a solar cell, and the solar cell manufactured thereby, the method comprising a step for manufacturing a laminate in which a first electrode layer, a hole transport layer (HTL), a photoactive layer, an electron transport layer, and a second electrode layer are laminated in order, wherein the hole transport layer or the electron transport layer is formed by applying and drying a dispersion including a dispersion solvent, a hydroxide, and a metal oxide surface-modified with a carboxylic acid (R-COOH).
2.WO/2022/139537POLYPEPTIDE SPECIFIC FOR MUCIN 1 AND USE THEREOF
WO 30.06.2022
Int.Class C07K 16/30
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
Appl.No PCT/KR2021/019790 Applicant LG CHEM, LTD. Inventor LEE, Ji Hyun
The present invention relates to a polypeptide binding to mucin 1, an isolated polynucleotide encoding same, a vector carrying the polynucleotide, and a cell including the vector. In addition, the present invention relates to a chimeric antigen receptor including the polypeptide binding to mucin 1, an isolated polynucleotide encoding the chimeric antigen receptor, a vector carrying the polynucleotide, an immune cell expressing the chimeric antigen receptor, a composition comprising same for treatment of cancer, and a method for treatment of cancer.
3.WO/2022/139552COMBINATION THERAPY OF INSULINOTROPIC PEPTIDE AND GLP-2, FOR PREVENTING OR TREATING SHORT BOWEL SYNDROME
WO 30.06.2022
Int.Class A61K 38/26
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
22Hormones
26Glucagons
Appl.No PCT/KR2021/019854 Applicant HANMI PHARM. CO., LTD. Inventor CHOI, Jae Hyuk
The present invention relates to a combination therapy of insulinotropic peptide and GLP-2, for preventing, alleviating or treating short bowel syndrome.
4.WO/2022/1405276-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS
WO 30.06.2022
Int.Class C07D 471/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
Appl.No PCT/US2021/064830 Applicant AJAX THERAPEUTICS, INC. Inventor MASSE, Craig E.
The present disclosure provides 6-heteroaryloxy benzimidazole and azabenzimidazole compounds and compositions thereof useful for inhibiting JAK2.
5.WO/2022/136222RECOMBINANT BACTERIUM AND USES THEREOF
WO 30.06.2022
Int.Class C07K 14/19
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
18Togaviridae, e.g. flavivirus, pestivirus, yellow fever virus, hepatitis C virus, japanese encephalitis virus
19Rubella virus
Appl.No PCT/EP2021/086708 Applicant CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) Inventor ASENSIO CALAVIA, Alejandro
The invention relates to a recombinant bacterium and uses thereof. In particular, it relates to the use of recombinant bacteria to translocate cargo proteins into the cytosol of target cells. Said recombinant bacteria comprises a T3 secretion system under the control of a genetic regulatory circuit and a targeting module which allow the recombinant bacteria to target specific cells, adhere to these and inject their cargo into the cytosol of the target cells.
6.WO/2022/136297NOVEL RECOMBINANT FRAGMENTS OF FIBRILLIN-1 AND METHODS OF USE THEREOF
WO 30.06.2022
Int.Class A61K 38/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
Appl.No PCT/EP2021/086848 Applicant INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM Inventor GENOT, Elisabeth
The present invention relates to novel recombinant fragments derived from the fibrillin-1 protein, which are particularly useful for their pro-angiogenic and vessel normalization properties, pharmaceutical compositions comprising said fragments and methods of use for the prevention and/or treatment of vascular diseases.
7.WO/2022/136582ANTIBODIES SPECIFIC FOR STRUCTURALLY DISORDERED SEQUENCES
WO 30.06.2022
Int.Class C07K 16/44
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
44against material not provided for elsewhere
Appl.No PCT/EP2021/087365 Applicant XL-PROTEIN GMBH Inventor SCHILZ, Jonas
The present invention relates to a method for generating and/or obtaining specific binding moieties against intrinsically disordered proteins (IDPs) and/or intrinsically disordered protein domains which tend to be immunologically inert and lack immunogenicity in animals, in particular in mammals. The present invention also relates to such specific binding moieties, in particular to antibodies and/or to antigen binding fragments thereof, specifically binding to structurally disordered and/or intrinsically disordered sequences, in particular to Pro/Ala-rich sequences (PAS). These binding moieties, antibodies, antigen binding fragments are first in class since they bind to/recognize disordered peptides or polypeptide fragments as also comprised in such "intrinsically disordered proteins", in particular PAS polypeptides. The inventive binding moieties, antibodies, antigen binding fragments are, without being limiting, particularly useful in diagnostic settings as well as research tools. The present invention relates to a method for generating and/or obtaining specific binding moieties against intrinsically disordered proteins (IDPs) and/or intrinsically disordered protein domains which tend to be immunologically inert and lack immunogenicity in animals, in particular in mammals. The present invention also relates to such specific binding moieties, in particular to antibodies and/or to antigen binding fragments thereof, specifically binding to structurally disordered and/or intrinsically disordered sequences, in particular to Pro/Ala-rich sequences (PAS). These binding moieties, antibodies, antigen binding fragments are first in class since they bind to/recognize disordered peptides or polypeptide fragments as also comprised in such "intrinsically disordered proteins", in particular PAS polypeptides. The inventive binding moieties, antibodies, antigen binding fragments are, without being limiting, particularly useful in diagnostic settings as well as research tools.
8.WO/2022/136642TUMOR-SPECIFIC CLAUDIN 18.2 ANTIBODY-DRUG CONJUGATES
WO 30.06.2022
Int.Class A61K 47/68
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
Appl.No PCT/EP2021/087495 Applicant SOTIO BIOTECH A.S. Inventor BAMMERT, Lukas
The invention provides an ADC based on an antibody binding to CLDN18.2, wherein the antibody or fragment thereof exhibits increased binding to tumor tissue expressing CLDN18.2 over healthy tissue expressing CLDN18.2.
9.WO/2022/136672ANTIBODY VARIABLE DOMAINS THAT BIND IL-31
WO 30.06.2022
Int.Class C07K 16/24
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
24against cytokines, lymphokines or interferons
Appl.No PCT/EP2021/087568 Applicant NUMAB THERAPEUTICS AG Inventor TIETZ, Julia
The present invention relates to an antibody variable domain, which specifically binds to IL-31, to multispecific antibodies comprising one or two of said antibody variable domains and at least one further binding domain that specifically binds to a target different from IL-31. The present invention further relates to a nucleic acid or two nucleic acids encoding said antibody variable domain or said multispecific antibody, vector(s) comprising said nucleic acids or said nucleic acids, host cell(s) comprising said nucleic acid or said nucleic acids or said vector(s), and a method of producing said antibody variable domain or said multispecific antibody. Additionally, the present invention relates to pharmaceutical compositions comprising said antibody variable domain or said multispecific antibody and to methods of use thereof.
10.WO/2022/134047HUMANIZED ANTI-C5 ANTIBODIES AND FACTOR H FUSION PROTEINS AND USES THEREOF
WO 30.06.2022
Int.Class C07K 16/18
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
Appl.No PCT/CN2020/139556 Applicant THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Inventor SONG, Wenchao
Provided is inhibition of the complement signaling using an anti-C5 antibody or fusion protein thereof. Specifically, provided are methods of treating a complement-mediated disease or complement-mediated disorder in an individual by contacting the individual with an anti-C5 antibody fusion protein thereof.